Culturelle® with Lactobacillus rhamnosus GG (LGG®) for infants

Digestive and immune support to promote a lifetime of health for infants

The infant’s developing gut microbiota can influence lifelong health

The microbiota plays an important role in the development of the immune system.1-3 Gut microbes prime the mucosal immune system and can also influence resistance to infection.1 Because of its involvement with and functions within the immune system, the microbiota has the potential to influence lifelong health. In support of this, multiple studies show that a poorly-colonized microbiota may be a root cause of many diseases, including Crohn’s disease and necrotizing enterocolitis.2

Gut health is about more than digestive health.


Insufficient microbial colonization of the intestinal tract can result in episodic or short-term consequences such as digestive discomfort, colic, infectious diarrhea, eczema, and food allergy as well as long-term or life-long consequences including atopic diseases, autoimmune diseases, neuropsychiatric disorders, and overall health.2-5

A variety of factors contribute to optimal colonization of the microbiota



  • Mode of delivery. A full-term, vaginal birth introduces beneficial microbes, including lactobacilli and bifidobacteria6-7
  • Cautious antibiotic use. Peripartum antibiotic use lowers the abundance of lactobacilli and bifidobacteria6-7
  • Breastfeeding. The prioritization and maximization of exclusive breastfeed for as long as possible promotes optimal microbial colonization6-7
  • Gestational age. Full-term infants have more a diverse microbiota and are less likely to have prolonged exposure to antibiotics6-7

When one or more of these factors isn’t met, probiotic supplementation may help support the developing gut microbiota.

The probiotics Lactobacillus rhamnosus GG (LGG®) and Bifidobacterium Lactis (BB-12) have each been extensively studied in infants and have proven benefits9-18

LGG® is a human derived probiotic strain and is well-established to be both safe and effective in infants.8-18  LGG® delivers both digestive and immune benefits and is clinically proven to foster the growth of additional beneficial bacteria.19   

Interested in additional clinical research and data for LGG® supplementation in infants?  Learn more

LGG® is highly recommended across medical community

The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) recommends LGG® supplementation for the prevention of:20-22

  • Antibiotic-associated diarrhea
  • Nosocomial diarrhea
  • Acute gastroenteritis

The Culturelle® Advantage

When compared to other probiotics, Culturelle® offers a more concentrated product with higher CFUs, includes additional ingredients for more medical benefits, and uses patented probiotic suspension to ensure consistent dosing.*

{CMS alt text}

Culturelle® offers safe and gentle probiotic products to support infants’ developing digestive and immune systems and promote healthy development*

Culturelle® offers a line-up of safe and gentle products specially-formulated to help reduce infant fussiness and crying due to occasional digestive upset and to help build a strong foundation for lifelong health.*

Explore our wide range of products and learn why Culturelle® is the #1 pediatrician recommended brand of probiotics. Learn more


  • Fulde M, MF.Hornef. Maturation of the enteric mucosal innate immune system during the postnatal period. Immunol Rev. 2014;260(1):21-34.
  • Francino MP. Early development of the gut microbiota and immune health. Pathogens. 2014;4:769-790.
  • Amenyogbe N, Kollmann TR, Ben-Othman R. Early-life host-microbiome interphase: the key frontier for immune development. Front Pediatr. 2017;5:1-12.
  • Stiemsma LT, Turvey SE. Asthma and the microbiome: defining the critical window in early life. Allergy Asthma Clin Immunol. 2017;13:3-12.
  • Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. 2016;352(6285):539-544.
  • Castanys-Munoz E, Martin MJ, Vazquez E. Building a beneficial microbiome from birth.  Adv. Nutr. 2016:7(2):323-330.  
  • Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during pregnancy, birth, and infancy.  Front Microbiol. 2016;7:1031.  
  • Kalliomäki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 200;357(9262):1076-1079.
  • Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361(9372):1869-1871.
  • Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119(4):1019-1021.
  • Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000;30(11):1604-1610.
  • Berni Canani R, Nocerino R, Terrin G, et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow's milk allergy: a randomized trial. J Allergy Clin Immunol. 2012;129(2):580-602.
  • Holscher HD, Czerkies LA, Cekola P, et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. J Parenter Enteral Nutr. 2012;36(1):106S-17S.
  • Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy--a randomised, double-blind, placebo-controlled study. Br J Nutr. 2009;101(11):1722-1726.
  • Raza S, Graham SM, Allen SJ, et al. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr Infect Dis J. 1995;14(2):107-111.
  • Szajewska H,  Kotowska M,  Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr. 2001;138 (3):361–365.
  • Pärtty A, Luoto R, Kalliomäki M, Salminen S, Isolauri E. Effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;163(5):1272-1277.
  • Dubois NE, Gregory KE. Characterizing the intestinal microbiome in infantile colic: Findings based on an integrative review of the literature. Biol Res Nurs. 2016;18(3):307-315.
  • Gueimonde M, Sakata S, Kalliomaki M, Isolauri, E, Benno Y, Salminin S. Effect of maternal consumption of Lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr. 2006;42(2):166-170.  
  • Szajewska H, Canani RB, Guarino A.Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. JPGN. 2016; 62(3):495-506.
  • Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014. JPGN.2014;59:132–152.
  • Hojsak I, Szajewska H, Canani RB, et al. Probiotics for the prevention of nosocomial diarrhea in children. JPGN. 2017. Published online. doi: 10.1097/MPG.0000000000001637.